BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2025 8:37:55 AM | Browse: 6 | Download: 0
 |
Received |
|
2025-04-21 03:31 |
|
Peer-Review Started |
|
2025-04-21 03:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-05-11 13:08 |
|
Revised |
|
2025-05-25 04:09 |
|
Second Decision |
|
2025-07-18 02:43 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-07-18 08:51 |
|
Articles in Press |
|
2025-07-18 08:51 |
|
Publication Fee Transferred |
|
2025-05-26 12:18 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-09-02 06:30 |
|
Publish the Manuscript Online |
|
2025-09-15 08:37 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Tian-Ao Zhan, Feng Xia, Hong-Wei Huang, Jun-Cheng Zhan, Xin-Kang Liu and Qi Cheng |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Chen Xiao-Ping Foundation for The Development of Science and Technology of Hubei Province |
CXPJJH124001-2406 |
| National Natural Science Foundation of China |
U23A20483 |
|
| Corresponding Author |
Qi Cheng, MD, PhD, Professor, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, Hubei Province, China. chengqi@hust.edu.cn |
| Key Words |
Hepatocellular carcinoma; Fibroblast growth factor 19; Selective fibroblast growth factor receptor 4 inhibitor; Adverse events; Resistance; Targeted-immunotherapy; Tumor microenvironment; Biomarker |
| Core Tip |
The aberrant Fibroblast growth factor 19 (FGF19)-fibroblast growth factor receptor 4 (FGFR4) axis plays a crucial role in progression of hepatocellular carcinoma. Multi-kinase inhibitors enhance anti-tumor effects by targeting the FGF19-FGFR4 axis and FGF19 overexpression contributes to the development of immune suppression. These findings highlight the association between FGF19 and targeted-immunotherapy in hepatocellular carcinoma (HCC). Selective FGFR4 inhibitors, either alone or combining with targeted-immunotherapy, have demonstrated therapeutic potential for advanced HCC, although the clinical application is hindered by challenges such as adverse effects and drug resistance. Furthermore, FGF19 serves as a promising biomarker for HCC, underscoring its potential for precision treatment. |
| Publish Date |
2025-09-15 08:37 |
| Citation |
<p>Zhan TA, Xia F, Huang HW, Zhan JC, Liu XK, Cheng Q. Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma. <i>World J Gastrointest Oncol</i> 2025; 17(9): 108649</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i9/108649.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i9.108649 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
